Moxifloxacino Tillomed (Moxifloxacin)

Moxifloxacin is a fluoroquinolone antibacterial indicated for several acute bacterial infections.

• Community‑acquired pneumonia: effective in achieving clinical cure and microbiological eradication.
• Acute bacterial sinusitis: reduces symptoms and clears the infecting pathogen.
• Acute bacterial exacerbation of chronic bronchitis: improves airflow and resolves infection.
• Skin and skin‑structure infections: promotes healing by eliminating causative bacteria.
• Complicated intra‑abdominal infections: assists in controlling polymicrobial infection after surgical intervention.

• Moxifloxacin exerts its antibacterial activity by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. Inhibition of these enzymes prevents the supercoiling and separation of DNA strands, halting bacterial cell division and ultimately leading to bacterial cell death. This dual‑target action provides broad‑spectrum activity against Gram‑positive, Gram‑negative, and atypical pathogens.

Moxifloxacin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertigo or light‑headedness.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Tendon rupture: sudden tendon pain or swelling, especially in the Achilles.
• QT interval prolongation: cardiac arrhythmia risk, manifested as palpitations.
• Severe hypersensitivity: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Clostridioides difficile colitis: severe diarrhea with abdominal pain.
• Hepatotoxicity: elevated liver enzymes or jaundice.

When prescribing Moxifloxacino Tillomed, clinicians should consider several safety precautions to minimize risk.

• Evaluate renal and hepatic function: adjust therapy if impairment is present.
• Avoid use in patients with known fluoroquinolone hypersensitivity: discontinue immediately if reaction occurs.
• Monitor for tendon pain or inflammation: discontinue if signs of tendonitis develop.
• Assess cardiac history: caution in patients with arrhythmias or electrolyte disturbances.
• Use with caution in pregnant or breastfeeding women: risk–benefit assessment required.
• Store at below 25°C: keep in original packaging, protect from moisture and light.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption; separate dosing by at least 2 hours.
• Warfarin: may increase INR; monitor coagulation parameters closely.
• Theophylline: increased plasma levels; watch for toxicity signs.

Moderate Interactions (Monitor Closely)

• NSAIDs (e.g., ibuprofen): may increase risk of central nervous system effects.
• Corticosteroids: heightened risk of tendon rupture.
• Cyclosporine: potential for increased serum concentrations.
• Oral hypoglycemics: may enhance blood‑glucose lowering effect.